Heather H. Cheng, MD, PhD, is Director of the Prostate Cancer Genetics Clinic and Associate Professor of Clinical Research in the division of Clinical Research at the Fred Hutch Cancer Center and Department of Medicine (Oncology) at the University of Washington. She is a medical oncologist who specializes in prostate cancer, with a clinical and translational research focus on the heritable (germline) and tumor-specific (somatic) genetics of prostate cancer. She conducts clinical trials with relevance to men with germline mutations in genes such as BRCA2, BRCA1 and other genes implicated in prostate cancer risk and aggressiveness, and that also serve as biomarkers for precision therapy. She leads the Prostate Cancer Clinical Trials Consortium (PCCTC)/Prostate Cancer Foundation (PCF) Germline Genetics Working Group, is member of the SWOG cooperative group and the National Cancer Institute (NCI) Genitourinary (GU) Steering Committee Task Force for Prostate Cancer, sits on the American Society of Clinical Oncology (ASCO) GU Education Committee and the National Comprehensive Cancer Network (NCCN) Guidelines Committee for Prostate Cancer Panel and for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Panel. For her collaborative accomplishments she was awarded an NCI Cancer Clinical Investigator Team Leadership Award in 2020. Dr. Cheng is passionate about advancing scientific discovery, medical innovation and equitable access for patients with BRCA mutations across the spectrum—patients, survivors of prostate cancer and previvors with prostate cancer risk.